Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Mechanism OOR agonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date08 Oct 2002 |
Mechanism Opioid receptors antagonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date17 Apr 1995 |
Target |
Mechanism Opioid receptors agonists |
Active Org. Rising Pharmaceuticals, Inc.Startup [+1] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date29 Dec 1986 |
Start Date30 Jun 2021 |
Sponsor / Collaborator |
Start Date01 Aug 2016 |
Sponsor / Collaborator AiCure LLC [+2] |
Start Date01 Aug 2013 |
Sponsor / Collaborator Orexo AB [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Buprenorphine Hydrochloride/Naloxone Hydrochloride ( OOR x κ opioid receptor x μ opioid receptor ) | Opium Dependence More | Approved |
Naloxone hydrochloride ( μ opioid receptor ) | Opiate Overdose More | NDA/BLA |
Sufentanil ( μ opioid receptor ) | Cancer Pain More | Phase 3 |
Vipoglanstat ( PGES ) | Endometriosis More | Phase 2 |
Adrenaline ( adrenergic receptor ) | Drug Hypersensitivity More | Phase 1 |